Endometriosis with FDG uptake on PET

Eur J Obstet Gynecol Reprod Biol. 2004 Dec 1;117(2):236-9. doi: 10.1016/j.ejogrb.2004.04.034.

Abstract

Background: The value of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) uptake in endometriosis has not yet been extensively reported.

Case report: A 32-year-old woman was examined to find an explanation for right pelvic pain associated with right subcostal pain. A computerised tomography (CT) scan was compatible with a haemangioma or a focus of endometriosis in the liver. Transvaginal sonography and magnetic resonance imaging (MRI) showed a complex ovarian cyst on the left. Blood CA125 levels were elevated. FDG-PET revealed a focus of uptake in the right paravesical area. Laparoscopy showed a left endometrioma associated with diffuse inflammatory pelvic adhesions. After surgery and 3 months GnRH agonist treatment the pain had disappeared and neither MRI nor FDG-PET showed any pelvic abnormality. The patient subsequently presented with dyspareunia and rectal pain resulting from a right uterosacral nodule and a rectal nodule. These were resected laparoscopically. After a 1-year follow-up, the patient is doing well.

Conclusion: Endometriosis can give rise to false-positive results on FDG-PET. However, the FDG uptake in this particular case of endometriosis seems to have been due to inflammation rather than to a cyst. This report highlights the relationship between some of the biological features of endometriosis and some observed in neoplastic lesions.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Pain / etiology
  • Adult
  • CA-125 Antigen / blood
  • Endometriosis / complications
  • Endometriosis / diagnosis*
  • Endometriosis / therapy
  • Endosonography
  • Female
  • Fluorodeoxyglucose F18*
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Gynecologic Surgical Procedures
  • Hormones / therapeutic use
  • Humans
  • Laparoscopy
  • Magnetic Resonance Imaging
  • Pelvic Pain
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Recurrence
  • Reoperation
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • CA-125 Antigen
  • Hormones
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Gonadotropin-Releasing Hormone